Addex reports third quarter 2024 financial results and provides corporate update

Indivior selected gaba b pam drug candidate for development in substance use disorders (sud) and starts ind enabling studies ad hoc announcement pursuant to art. 53 lr geneva, switzerland, november 22, 2024 - addex therapeutics (six/nasdaq: adxn), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its third quarter financial results for the periods ended september 30, 2024, and provided a corporate update.
ADXN Ratings Summary
ADXN Quant Ranking